Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933904 · ClinicalTrials.gov registry record · Phase 2
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
A Phase 2 study of Castleman Disease and Castleman's Disease, Multicentric, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 2
- Study locations
NCT03933904 is a Phase 2 study of Castleman Disease and Castleman's Disease, Multicentric that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 7 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT03933904, a Phase 2 study of Castleman Disease and Castleman's Disease, Multicentric, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (2)
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2019-09-25 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03933904
The ClinicalTrials.gov registry entry for NCT03933904 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Castleman Disease appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT03933904 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arkansas, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03933904 about?
NCT03933904 is a clinical study titled "Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease". The purpose of this study is to understand the impact of sirolimus on idiopathic multicentric Castleman disease.
What is the current status of trial NCT03933904?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2019-09-25. Estimated completion is 2026-06-30.
What conditions does trial NCT03933904 study?
This clinical trial studies the following conditions: Castleman Disease, Castleman's Disease, Multicentric.
What interventions are being tested in trial NCT03933904?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT03933904?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03933904 being conducted?
This trial has 2 study locations across Arkansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castleman Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.